You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • FRI0224 Comparison of Efficacy and Safety of Rituximab Biosimilar, BCD-020, and Innovator Rituximab in Patients with Active Rheumatoid Arthritis Refractory To TNFA Inhibitors

Citation Tools

Article menu
Download PDFPDF
Poster Presentations
Rheumatoid arthritis - other biologic treatment
FRI0224 Comparison of Efficacy and Safety of Rituximab Biosimilar, BCD-020, and Innovator Rituximab in Patients with Active Rheumatoid Arthritis Refractory To TNFA Inhibitors

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Eremeeva A, Chernyaeva E, Ivanov R, et al
FRI0224 Comparison of Efficacy and Safety of Rituximab Biosimilar, BCD-020, and Innovator Rituximab in Patients with Active Rheumatoid Arthritis Refractory To TNFA Inhibitors
Annals of the Rheumatic Diseases 2016;75:513-514.